Study details
Enrolling now
Pregabalin Plus Lofexidine for Opioid Withdrawal
University of Pennsylvania
NCT IDNCT05995535ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
150
Study length
about 2.7 years
Ages
18+
Locations
2 sites in MD, PA
What this study is about
This trial is testing whether lofexidine plus pregabalin helps manage opioid withdrawal symptoms in adults. Participants will receive either lofexidine/pregabalin or a placebo, and may be offered extended-release injectable naltrexone after completing the withdrawal period.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take LFX/PGB
- 2.Take LFX/PLA-PGB
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Body systems
Psychiatry / Mental Health